• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Other Gynecological Disorders - Pipeline Review, H2 2012 Product Image

Other Gynecological Disorders - Pipeline Review, H2 2012

  • Published: September 2012
  • 51 pages
  • Global Markets Direct

Other Gynecological Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Other Gynecological Disorders - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Other Gynecological Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Gynecological Disorders. Other Gynecological Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Gynecological Disorders.
- A review of the Other Gynecological READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Other Gynecological Disorders Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Other Gynecological Disorders 8
Other Gynecological Disorders Therapeutics under Development by Companies 10
Other Gynecological Disorders Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Other Gynecological Disorders Therapeutics – Products under Development by Companies 17
Other Gynecological Disorders Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Other Gynecological Disorders Therapeutics Development 19
Teva Pharmaceutical Industries Limited 19
Asterand plc. 20
Other Gynecological Disorders – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
estriol - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
oral cinnamon extract - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
immune globulin intravenous pentetate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DR-105 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
methenamine hippurate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
hydroxyprogesterone caproate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
josamycin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
fenugreek - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
medroxyprogesterone + venlafaxine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
metoclopramide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
isosorbide mononitrate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
dexamethasone acetate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
misoprostol - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Other Gynecological Disorders Therapeutics – Drug Profile Updates 41
Other Gynecological Disorders Therapeutics – Discontinued Products 42
Other Gynecological Disorders Therapeutics - Dormant Products 43
Other Gynecological Disorders – Product Development Milestones 44
Featured News & Press Releases 44
Jul 13, 2010: K-V Pharmaceutical Reports Resubmission To New Drug Application For Gestiva 44
Jun 08, 2010: Columbia Completes Enrollment In Phase III Study Of Prochieve 8% To Reduce Preterm Birth 44
Oct 12, 2009: Depomed Reports Results From Two Phase 3 Clinical Trials Evaluating Non-Hormonal Therapy For Menopausal Hot Flashes 45
Oct 06, 2009: Vantia Therapeutics’ VA111913 Enters Phase II Proof-­-Of-­-Concept Trials For Dysmenorrhoea 45
Jul 14, 2009: Noven Reports Positive Phase II Results For Mesafem 46
Apr 02, 2009: Depomed Completes Enrollment Of Serada's Full Phase 3 Clinical Program In Menopausal Hot Flashes 46
Mar 24, 2009: Radius Initiates Phase 2a Clinical Trial Of RAD1901 In Menopausal Hot Flashes 47
Dec 20, 2008: Depomed Initiates Second Phase 3 Trial In Menopausal Hot Flashes 48
Nov 17, 2008: PDC Biotech GmbH Reports Progress On Preterm Labour And Primary Dysmenhorrea Programs At BioEurope. 48
Sep 30, 2008: PDC Biotech GmbH Reports Progress on Preclinical Program for PDC31 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
Number of Products Under Development for Other Gynecological Disorders, H2 2012 8
Products under Development for Other Gynecological Disorders – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Teva Pharmaceutical Industries Limited, H2 2012 19
Asterand plc., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Other Gynecological Disorders Therapeutics – Drug Profile Updates 41
Other Gynecological Disorders Therapeutics – Discontinued Products 42
Other Gynecological Disorders Therapeutics – Dormant Products 43

List of Figures
Number of Products under Development for Other Gynecological Disorders, H2 2012 8
Products under Development for Other Gynecological Disorders – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos